A medical report published in General Thoracic and Cardiovascular Surgery Cases details a rare clinical presentation of delayed drug-induced interstitial lung disease arising more than three months after the cessation of preoperative chemoimmunotherapy for operable primary lung cancer. The case involved a sixty-four-year-old male patient who underwent neoadjuvant treatment comprising three cycles of carboplatin, pemetrexed, and the immune checkpoint inhibitor nivolumab prior to definitive surgical resection. While immune checkpoint inhibitors have increasingly been integrated into perioperative protocols for early-stage and locally advanced malignancies, late-onset pulmonary toxicities emerging after significant treatment-free intervals present complex diagnostic challenges that require rigorous clinical surveillance.
Neoadjuvant chemoimmunotherapy has gained clinical adoption following evidence from multiple phase three clinical trials, including the CheckMate-816, KEYNOTE-671, and AEGEAN investigations. However, systemic checkpoint inhibition fundamentally alters regulatory immune pathways, occasionally causing persistent or delayed autoimmune manifestations known as immune-related adverse events, which can affect pulmonary, endocrine, or cardiovascular tissues months or years after the cessation of therapy.
Diagnostic evaluation via transbronchial lung biopsy conducted in August 2024 confirmed a diagnosis of lung adenocarcinoma, clinically staged as cT4N0M0, representing stage IIIA disease with an primary tumor measuring seventy-three millimeters in maximum diameter. In September 2024, clinicians initiated preoperative systemic treatment consisting of three cycles of carboplatin, pemetrexed, and nivolumab. Restaging computed tomography demonstrated a partial therapeutic response, with the primary left upper lobe mass regressing from an initial dimension of seventy-three by fifty-eight millimeters down to forty-six by twenty-eight millimeters prior to surgical intervention.
Surgical resection was performed in December 2024, four months following the initiation of systemic treatment. The operative procedure required an operative time of 311 minutes, with an estimated intraoperative blood loss of 115 milliliters. Postoperative histopathological examination of the resected tissue specimen revealed a diagnosis of large-cell neuroendocrine carcinoma featuring adenocarcinoma components, classified pathologically as y-pathological stage T2bN0M0 (stage IIB) with a residual tumor diameter of fifty millimeters and a calculated pathological treatment response rate of thirty percent.
The immediate postoperative recovery was complicated by hoarseness attributable to recurrent laryngeal nerve palsy, as well as systemic hypoxemia that necessitated the temporary prescription of home oxygen therapy. However, on postoperative day fifty-six, approximately eight weeks following surgical resection, the patient returned to the hospital presenting with acute exacerbation of shortness of breath. Diagnostic chest computed tomography revealed prominent infiltrate localized to the right lower lobe, while initial laboratory investigations showed a peripheral white blood cell count of 5.1 times 10 cubed per microliter and a C-reactive protein elevation of 7.55 milligrams per liter.
Because the clinical presentation coincided with known postoperative recurrent laryngeal nerve dysfunction, medical staff initially diagnosed the condition as aspiration pneumonia. Empirical antimicrobial therapy was administered consisting of intravenous sulbactam and ampicillin at a dosage of three grams three times daily for one week. Despite continuous antibiotic administration, the patient experienced no subjective or functional improvement in respiratory symptoms. Subsequent laboratory evaluations showed a persistent systemic inflammatory response, with a white blood cell count of 3.8 times 10 cubed per microliter and C-reactive protein measured at 7.04 milligrams per liter, accompanied by a marked elevation in serum Krebs von den Lungen-6 (KL-6) levels to 943.9 units per milliliter.
Follow-up computed tomography imaging acquired on postoperative day sixty-three revealed clear progression and worsening of interstitial opacities and infiltrates within the right lower lung field rather than resolution. Based on the lack of response to antibacterial agents, progressive radiological worsening, and significantly elevated KL-6 concentrations, the medical team suspected late-onset drug-induced interstitial lung disease. The definitive diagnosis was established 196 days following the patient’s initial dose of immune checkpoint inhibition and 104 days after the final administration of neoadjuvant chemoimmunotherapy, representing an unusually prolonged latency period for primary pulmonary toxicity.
Management of the delayed pulmonary toxicity was initiated in accordance with clinical practice guidelines established by the American Society of Clinical Oncology and the European Society for Medical Oncology. Following pulse therapy, oral steroid maintenance therapy was established at a dose of one milligram per kilogram of body weight.
Checkpoint inhibitors such as nivolumab function by blocking inhibitory signaling through the programmed cell death 1 (PD-1) pathway on antitumor T cells, thereby enhancing cellular immune responses. Pharmacokinetic studies show that although the circulating serum half-life of nivolumab spans approximately 12 to 20 days, sustained receptor occupancy on circulating T cells remains remarkably stable at roughly 80 percent for up to 90 days following a single administration. Even after only three doses, PD-1 receptor occupancy can remain at approximately 40 percent more than eight months after the final infusion, providing a plausible biological basis for delayed immunotoxic reactions.
Published literature reviews, including retrospective analyses of clinical trials by Couey and colleagues, have documented instances where immune-related toxicities developed 90 days or longer following treatment cessation, with a median onset occurring six months after drug discontinuation. Furthermore, epidemiological evaluations by Durbin and colleagues noted that significant proportions of hospitalizations for immune toxicities take place six to twelve months or beyond one year following treatment initiation. Ten months after surgery, the reported patient’s steroid dosage was successfully tapered to seven milligrams daily without symptom recurrence or supplemental oxygen requirements, underscoring the critical need for prolonged, vigilant postoperative monitoring across multidisciplinary surgical and oncological care teams.
The cumulative clinical evidence regarding checkpoint inhibitor toxicities highlights the broad timeline over which patients may remain vulnerable to systemic complications. In published evaluations of immune-related adverse events, researchers tracked cumulative probabilities following the start of immunotherapy, recording rates of 42.8 percent at six months, 51.0 percent at twelve months, and 57.3 percent at twenty-four months after treatment initiation. Furthermore, among patient cohorts requiring inpatient admission for severe immune complications, 14.7 percent experienced onset within six to twelve months following their initial dose, and 10.8 percent developed symptoms more than one full year after initiating therapy. These statistical distributions confirm that clinical risks do not abruptly terminate when active infusions cease, indicating that certain patients require acute inpatient care for toxicities emerging several years into follow-up.
The range and severity of these delayed immunological phenomena span multiple organ systems, requiring distinct therapeutic and supportive strategies depending on the affected tissue. In addition to chronic endocrine damage, systemic immune activation may manifest as fulminant, life-threatening pathologies, including acute exacerbations of interstitial lung disease and severe myocarditis.
In surgical contexts, early diagnostic ambiguity remains a primary operational obstacle when evaluating respiratory deterioration after lung resection. In the reported case, the patient presented with hoarseness from vocal cord paresis alongside right lower lobe consolidation, which naturally prompted immediate empirical coverage for bacterial aspiration.
Following definitive recognition, adherence to established oncology clinical practice guidelines published by organizations such as the American Society of Clinical Oncology and the European Society for Medical Oncology enabled rapid, successful therapeutic intervention. With the patient maintaining stable outpatient status without recurrence ten months post-resection, clinicians stress that vigilance for immune-related adverse events must persist across all medical disciplines regardless of the brevity of preoperative regimens or the elapsed time since drug discontinuation.
Subject of Research: Delayed drug-induced interstitial lung disease following neoadjuvant chemoimmunotherapy in primary lung cancer
Article Title: Primary lung cancer with delayed drug-induced interstitial lung disease after neoadjuvant chemoimmunotherapy: a case report
Article References: Ichinokawa, H., Sowa, T., Yaguchi, T., Watanabe, Y., Takamochi, K., & Suzuki, K. (2026). Primary lung cancer with delayed drug-induced interstitial lung disease after neoadjuvant chemoimmunotherapy: a case report. General Thoracic and Cardiovascular Surgery Cases, 5(1), Article 7. https://doi.org/10.1186/s44215-026-00247-4
Image Credits: AI Generated
DOI: 10.1186/s44215-026-00247-4
Keywords: lung cancer, neoadjuvant chemoimmunotherapy, nivolumab, carboplatin, pemetrexed, interstitial lung disease, immune-related adverse events, lobectomy, adenocarcinoma, large-cell neuroendocrine carcinoma, KL-6 biomarker, c-reactive protein, corticosteroid therapy, thoracic surgery, postoperative complications, programmed cell death receptor
News Source: Nathaniel Bowman. (November 13, 2026). Case Study Documents Delayed Lung Disease Following Preoperative Cancer Immunotherapy. Scienmag.



